{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:30:34Z","timestamp":1792218634445,"version":"4.4.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:00:00Z","timestamp":1758931200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Gilead Sciences, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Sacituzumab govitecan (SG) is a first-in-class trophoblast cell surface antigen-2-directed antibody-drug conjugate that selectively delivers a well-characterized and potent payload of SN-38 to cancer cells and the surrounding environment. In the United States, SG is indicated for unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC) and hormone receptor-positive (HR+)\/human epidermal growth factor receptor 2-negative (immunohistochemistry 0, 1+, or 2+\/in situ hybridization-negative) breast cancer (HR+\/HER2\u2212 BC). Real-world management of SG-related adverse events can vary widely from clinical studies. Therefore, it is vital to provide clinicians with first-hand experience to aid in the management and support of patients before treatment initiation. In clinical studies (IMMU-132-01, ASCENT, TROPiCS-02, and TROPHY-U-01), the pooled incidence of key adverse events was 61% for neutropenia, 64% for diarrhea, 51% for fatigue, and 45% for alopecia. Here, we discuss the incidence of neutropenia, diarrhea, fatigue, and alopecia associated with SG treatment and provide recommendations on their management based on established guidelines and personal clinical experience. We also discuss important risk factors such as UGT1A1 polymorphism and advanced age (eg, \u226565 years). From our practical experience, we present a case of a patient with TNBC experiencing neutropenia and diarrhea, and another with HR+\/HER2\u2212 BC experiencing diarrhea. Our review provides practicing oncologists considering SG therapy important information regarding its safe and appropriate use in real-world settings to maximize clinical benefit for patients with locally advanced or metastatic TNBC and HR+\/HER2\u2212 BC.<\/jats:p>","DOI":"10.1093\/oncolo\/oyaf311","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T12:24:31Z","timestamp":1758716671000},"source":"Crossref","is-referenced-by-count":10,"title":["Clinical perspective on management of key adverse events with sacituzumab govitecan"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5940-8671","authenticated-orcid":false,"given":"Sara M","family":"Tolaney","sequence":"first","affiliation":[{"name":"Dana-Farber Cancer Institute , Boston, MA 02115,","place":["United States"]},{"name":"Harvard Medical School , Boston, MA 02115,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1010-9611","authenticated-orcid":false,"given":"Guru P","family":"Sonpavde","sequence":"additional","affiliation":[{"name":"AdventHealth Cancer Institute , Orlando, FL 32804,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8686-0228","authenticated-orcid":false,"given":"Paolo","family":"Tarantino","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute , Boston, MA 02115,","place":["United States"]},{"name":"Harvard Medical School , Boston, MA 02115,","place":["United States"]},{"name":"Department of Oncology and Onco-Hematology, University of Milan , Milan 20122,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam B","family":"Lustberg","sequence":"additional","affiliation":[{"name":"Yale Cancer Center , New Haven, CT 06510,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope S","family":"Rugo","sequence":"additional","affiliation":[{"name":"Department of Medicine (Hematology\/Oncology), University of California-San Francisco Helen Diller Family Comprehensive Cancer Center , San Francisco, CA 94158,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"2025111615471338200_oyaf311-B1","doi-asserted-by":"publisher","first-page":"22496","DOI":"10.18632\/oncotarget.4318","article-title":"Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)","volume":"6","author":"Goldenberg","year":"2015","journal-title":"Oncotarget"},{"key":"2025111615471338200_oyaf311-B2","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.2147\/OTT.S162447","article-title":"Targeting Trop-2 in solid tumors: future prospects","volume":"12","author":"Zaman","year":"2019","journal-title":"Onco Targets Ther"},{"key":"2025111615471338200_oyaf311-B3","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","article-title":"Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann Oncol"},{"key":"2025111615471338200_oyaf311-B4","first-page":"2182","article-title":"Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)","volume":"7","author":"Mathijssen","year":"2001","journal-title":"Clin Cancer Res"},{"key":"2025111615471338200_oyaf311-B5","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1158\/1535-7163.MCT-22-0375","article-title":"Antibody-drug conjugate sacituzumab govitecan drives efficient tissue penetration and rapid intracellular drug release","volume":"22","author":"Kopp","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"2025111615471338200_oyaf311-B6","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N Engl J Med"},{"key":"2025111615471338200_oyaf311-B7","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/j.annonc.2020.09.004","article-title":"Sacituzumab govitecan in previously treated hormone receptor-positive\/HER2-negative metastatic breast cancer: final results from a phase I\/II, single-arm, basket trial","volume":"31","author":"Kalinsky","year":"2020","journal-title":"Ann Oncol"},{"key":"2025111615471338200_oyaf311-B8","doi-asserted-by":"publisher","first-page":"3843","DOI":"10.1002\/cncr.30789","article-title":"Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinetics","volume":"123","author":"Ocean","year":"2017","journal-title":"Cancer"},{"key":"2025111615471338200_oyaf311-B9","author":"Gilead Sciences, Inc","year":"2025"},{"key":"2025111615471338200_oyaf311-B10","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"key":"2025111615471338200_oyaf311-B11","doi-asserted-by":"publisher","first-page":"103756","DOI":"10.1016\/j.breast.2024.103756","article-title":"6th and 7th international consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)","volume":"76","author":"Cardoso","year":"2024","journal-title":"Breast"},{"key":"2025111615471338200_oyaf311-B12","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1200\/JCO.22.01002","article-title":"Sacituzumab govitecan in hormone receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"40","author":"Rugo","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025111615471338200_oyaf311-B13","doi-asserted-by":"publisher","first-page":"102670","DOI":"10.1016\/j.ctrv.2023.102670","article-title":"Current and emerging treatment approaches for hormone receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"123","author":"Jhaveri","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"2025111615471338200_oyaf311-B14","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1200\/JCO.22.02807","article-title":"Chemotherapy and targeted therapy for endocrine-pretreated or hormone receptor-negative metastatic breast cancer: ASCO guideline rapid recommendation update","volume":"41","author":"Moy","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025111615471338200_oyaf311-B15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ejca.2022.10.003","article-title":"Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer","volume":"178","author":"Loibl","year":"2023","journal-title":"Eur J Cancer"},{"key":"2025111615471338200_oyaf311-B16","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"key":"2025111615471338200_oyaf311-B17","doi-asserted-by":"publisher","first-page":"5131","DOI":"10.1158\/1078-0432.CCR-15-0670","article-title":"Enhanced delivery of SN-38 to human tumor xenografts with an anti-trop-2-SN-38 antibody conjugate (sacituzumab govitecan)","volume":"21","author":"Sharkey","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2025111615471338200_oyaf311-B18","doi-asserted-by":"publisher","first-page":"PO5-21-09","DOI":"10.1158\/1538-7445.SABCS23-PO5-21-09","article-title":"Clinical outcomes by age subgroups in the phase 3 TROPiCS-02 study of sacituzumab govitecan vs treatment of physician\u2019s choice in HR+\/HER2- metastatic breast cancer","author":"Bardia","year":"2024","journal-title":"Cancer Res"},{"key":"2025111615471338200_oyaf311-B19","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1200\/JCO.2024.42.16_suppl.3029","article-title":"Pooled safety analysis of sacituzumab govitecan in multiple solid tumor models","author":"Rugo","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025111615471338200_oyaf311-B20","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrclinonc.2014.127","article-title":"Cancer-related fatigue\u2014mechanisms, risk factors, and treatments","volume":"11","author":"Bower","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"2025111615471338200_oyaf311-B21","doi-asserted-by":"publisher","first-page":"5556","DOI":"10.3390\/cancers13215556","article-title":"Cancer-related alopecia: from etiologies to global management","volume":"13","author":"Quesada","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025111615471338200_oyaf311-B22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2147\/PGPM.S108656","article-title":"UGT1A1 polymorphisms in cancer: impact on irinotecan treatment","volume":"10","author":"Takano","year":"2017","journal-title":"Pharmgenomics Pers Med"},{"key":"2025111615471338200_oyaf311-B23","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1200\/OP.21.00624","article-title":"All you need to know about UGT1A1 genetic testing for patients treated with irinotecan: a practitioner-friendly guide","volume":"18","author":"Karas","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"2025111615471338200_oyaf311-B24","doi-asserted-by":"publisher","first-page":"101383","DOI":"10.1016\/j.esmoop.2023.101383","article-title":"Safety outcomes by UGT1A1 status in the phase 3 TROPiCS-02 study of sacituzumab govitecan in HR+\/HER2\u2212 metastatic breast cancer","author":"Marme","year":"2023","journal-title":"ESMO Open"},{"key":"2025111615471338200_oyaf311-B25","doi-asserted-by":"publisher","first-page":"PS11-09","DOI":"10.1158\/1538-7445.SABCS20-PS11-09","article-title":"Impact of UGT1A1 status on the safety profile of sacituzumab govitecan in the phase 3 ASCENT study in patients with metastatic triple-negative breast cancer","author":"Rugo","year":"2021","journal-title":"Cancer Res"},{"key":"2025111615471338200_oyaf311-B26","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41523-022-00467-1","article-title":"Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"8","author":"Rugo","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"2025111615471338200_oyaf311-B27","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jgo.2015.12.002","article-title":"Comorbidity in older adults with cancer","volume":"7","author":"Williams","year":"2016","journal-title":"J Geriatr Oncol"},{"key":"2025111615471338200_oyaf311-B28","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025111615471338200_oyaf311-B29","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1200\/JCO.2024.42.16_suppl.1101","article-title":"Prevention of sacituzumab govitecan (SG)-related neutropenia and diarrhea in patients (PTS) with triple-negative or HR+\/HER2\u2212 advanced breast cancer (ABC; PRIMED): a phase 2 trial","volume":"42","author":"Perez-Garcia","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025111615471338200_oyaf311-B30","doi-asserted-by":"publisher","first-page":"P3-07-08","DOI":"10.1158\/1538-7445.SABCS22-P3-07-08","article-title":"Exposure-adjusted incidence rates (EAIRs) of adverse events (AEs) from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician\u2019s choice (TPC) in HR+\/HER2\u2212 metastatic breast cancer (MBC)","volume":"83","author":"Tolaney","year":"2023","journal-title":"Cancer Res"},{"key":"2025111615471338200_oyaf311-B31","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update","volume":"33","author":"Smith","year":"2015","journal-title":"J Clin Oncol"},{"key":"2025111615471338200_oyaf311-B32","doi-asserted-by":"publisher","first-page":"v248","DOI":"10.1093\/annonc\/mdq195","article-title":"Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications","volume":"21 Suppl 5","author":"Crawford","year":"2010","journal-title":"Ann Oncol"},{"key":"2025111615471338200_oyaf311-B33","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41416-021-01589-2","article-title":"Integration of DNA sequencing with population pharmacokinetics to improve the prediction of irinotecan exposure in cancer patients","volume":"126","author":"Karas","year":"2022","journal-title":"Br J Cancer"},{"key":"2025111615471338200_oyaf311-B34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.mmcr.2017.07.007","article-title":"Saccharomyces cerevisiae var. boulardii fungemia following probiotic treatment","volume":"18","author":"Appel-da-Silva","year":"2017","journal-title":"Med Mycol Case Rep"},{"key":"2025111615471338200_oyaf311-B35","doi-asserted-by":"publisher","first-page":"101446","DOI":"10.1016\/j.esmoop.2023.101446","article-title":"A phase 2 trial of loperamide and granulocyte colony-stimulating factors to improve sacituzumab govitecan tolerance in patients with unresectable locally advanced or metastatic triple-negative breast cancer: PRIMED","author":"Perez-Garcia","year":"2023","journal-title":"ESMO Open"},{"key":"2025111615471338200_oyaf311-B36"},{"key":"2025111615471338200_oyaf311-B37"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf311\/64417016\/oyaf311.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/11\/oyaf311\/64417016\/oyaf311.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/11\/oyaf311\/64417016\/oyaf311.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T20:47:18Z","timestamp":1763326038000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf311\/8266656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,11]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf311","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,9,26]]},"article-number":"oyaf311"}}